U.S. flag

An official website of the United States government

NM_172107.4(KCNQ2):c.322G>A (p.Val108Met) AND not provided

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jan 12, 2018
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000424454.4

Allele description [Variation Report for NM_172107.4(KCNQ2):c.322G>A (p.Val108Met)]

NM_172107.4(KCNQ2):c.322G>A (p.Val108Met)

Gene:
KCNQ2:potassium voltage-gated channel subfamily Q member 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
20q13.33
Genomic location:
Preferred name:
NM_172107.4(KCNQ2):c.322G>A (p.Val108Met)
HGVS:
  • NC_000020.11:g.63446812C>T
  • NG_009004.2:g.30829G>A
  • NM_004518.6:c.322G>A
  • NM_172106.3:c.322G>A
  • NM_172107.4:c.322G>AMANE SELECT
  • NM_172108.5:c.322G>A
  • NM_172109.3:c.322G>A
  • NP_004509.2:p.Val108Met
  • NP_742104.1:p.Val108Met
  • NP_742105.1:p.Val108Met
  • NP_742106.1:p.Val108Met
  • NP_742107.1:p.Val108Met
  • NC_000020.10:g.62078165C>T
  • NM_172107.2:c.322G>A
Protein change:
V108M
Links:
dbSNP: rs749164961
NCBI 1000 Genomes Browser:
rs749164961
Molecular consequence:
  • NM_004518.6:c.322G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_172106.3:c.322G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_172107.4:c.322G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_172108.5:c.322G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_172109.3:c.322G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000534672GeneDx
criteria provided, single submitter

(GeneDx Variant Classification (06012015))
Uncertain significance
(Jan 12, 2018)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From GeneDx, SCV000534672.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

A variant of uncertain significance has been identified in the KCNQ2 gene. The V108M variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to ourknowledge. This variant is observed in 2/111464 (0.002%) alleles from individuals of Europeanbackground in large population cohorts (Lek et al., 2016). In-silico analyses, including proteinpredictors and evolutionary conservation, support a deleterious effect. Additionally, missense variants in nearby residues have been reported in individuals with KCNQ2-related disorders (Stenson et al., 2014; Hortigüela et al., 2016). Furthermore, this substitution is predicted to be within thetransmembraine segment S1. However, the V108M variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024